Skip Navigation


European Heart Journal Advance Access originally published online on October 11, 2005
European Heart Journal 2005 26(24):2611-2613; doi:10.1093/eurheartj/ehi597
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
26/24/2611    most recent
ehi597v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Squire, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Squire, I.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2005. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Managing patients with heart failure: the reality of clinical practice

Iain Squire*

Department of Cardiovascular Sciences, University of Leicester, Leicester LE 1 7LX, UK

* E-mail address: is11@le.ac.uk

This editorial refers to ‘Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure’{dagger} by M.J. Lenzen et al., on page 2706

The first 150 words of the full text of this article appear below.

The medical community should, by now, be well aware of the importance of chronic heart failure (CHF), an increasingly common condition with high morbidity and mortality. We know that for patients with CHF in clinical trials, meaningful mortality and morbidity benefits are obtained with angiotensin-converting enzyme (ACE) inhibitors (or alternatively angiotensin receptor blockers), ß-blockers, and aldosterone antagonists. The accumulated body of evidence for the efficacy of these treatments in CHF is powerful. Guideline documents from national and international societies1 endorse the evidence, guide and encourage physicians to prescribe evidence-based therapies, and, to a large extent, define the expected standards of care.

These guidelines have for some years recommended that the ‘routine’ management of patients with CHF with left ventricular systolic dysfunction (LVSD) should include both ACE-inhibitor and ß-blocker, unless contraindicated. However, observational studies consistently indicate that large proportions of patients with CHF do not receive these therapies.2 It is often . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure
Mattie J. Lenzen, Eric Boersma, Wilma J.M. Scholte op Reimer, Aggie H.M.M. Balk, Michel Komajda, Karl Swedberg, Ferenc Follath, Manuel Jimenez-Navarro, Maarten L. Simoons, and John G.F. Cleland
EHJ 2005 26: 2706-2713. [Abstract] [FREE Full Text]